2023-09-07 14:12:54 ET
More on AbbVie, Alector, etc.
- AbbVie: Proving The Bears Wrong Again As Shares Surged
- AbbVie Unleashed: 4% Yield, Potentially 40% Undervalued
- AbbVie: Balance Is Everything
- AbbVie: Still A Buy According To Buffett's 10xEBT Rule
- AbbVie Inc. 2023 Q2 - Results - Earnings Call Presentation
- Alector, Inc. ( ALEC ) Q2 2023 Earnings Call Transcript
- Abbott Labs Vs AbbVie: Which One Is The Best Investment Choice?
- Unveiling AbbVie's Hidden Risks: Cautionary Notes For Investors
- AbbVie immunology chief to lead Novartis commercial operations
- Why is big pharma unmoved despite Medicare pricing threat?
- Republicans say Medicare drug negotiations will mean fewer new meds
- AbbVie seeks US, EU approval for Skyrizi for ulcerative colitis
For further details see:
Alector completes enrollments in mid-stage Alzheimer’s trial